Myositis Trials

The Division of Rheumatology strives to understand more myositis through research.  Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 

 

Study Name/IRB#/PIBrief DescriptionBasic Eligibility CriteriaContact
Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease (Attack My-ILD) ​
17-2000
The purpose of the 
study is to research a new treatment 
(Abatacept) 
for Myositis related interstitial lung 
disease (ILD)
To qualify for study 
participation, you must be:
  • Over 18 years old​
  • Diagnosed with Myositis Interstitial Lung Disease (ILD)
  • Not pregnant or breastfeeding
303-724-0581;
or email
Mallary Crow Adams

Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length.  A visit to determine an individuals eligibility may be required.  A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.​​